1. Home
  2. ATNI vs TECX Comparison

ATNI vs TECX Comparison

Compare ATNI & TECX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ATN International Inc.

ATNI

ATN International Inc.

N/A

Current Price

$23.63

Market Cap

392.6M

ML Signal

N/A

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

N/A

Current Price

$33.99

Market Cap

393.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
ATNI
TECX
Founded
1987
2019
Country
United States
United States
Employees
N/A
51
Industry
Telecommunications Equipment
Sector
Telecommunications
Exchange
Nasdaq
Nasdaq
Market Cap
392.6M
393.0M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
ATNI
TECX
Price
$23.63
$33.99
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$80.40
AVG Volume (30 Days)
65.7K
552.9K
Earning Date
06-08-2026
01-01-0001
Dividend Yield
4.55%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$729,075,000.00
N/A
Revenue This Year
$3.60
N/A
Revenue Next Year
$1.35
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.76
$13.70
52 Week High
$30.45
$35.99

Technical Indicators

Market Signals
Indicator
ATNI
TECX
Relative Strength Index (RSI) 35.68 75.47
Support Level $21.15 $16.83
Resistance Level $23.76 N/A
Average True Range (ATR) 1.31 2.45
MACD -0.71 1.27
Stochastic Oscillator 10.25 87.37

Price Performance

Historical Comparison
ATNI
TECX

About ATNI ATN International Inc.

ATN International Inc is a telecommunications and utilities company. The company provides digital infrastructure and communications services with a focus on rural and remote markets in the United States, and internationally, including Bermuda and the Caribbean region. Its operating segments comprise U.S. Telecom and International Telecom. The company earns revenue from its International telecommunication segment.

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

Share on Social Networks: